4021:TSENissan Chemical Corporation Analysis
Data as of 2026-03-14 - not real-time
SAR 5.60
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at SAR 5.60, which sits below the 20‑day SMA (5.83) and the 50‑day SMA (6.10) and is well under the 200‑day SMA (7.17), indicating a short‑term bearish price pressure. Technical signals are mixed: the RSI is at 40, suggesting modest downside momentum, while the MACD histogram is positive, hinting at a potential near‑term bounce. Support is identified around SAR 5.33 and resistance near SAR 6.65, framing a narrow trading range. On the fundamentals side, revenue has surged 42.7% year‑over‑year, though gross margins (29.4%) and operating margins (15.7%) remain modest. The company distributes a hefty dividend yield of 16.07% with a low payout ratio of 25%, supported by strong cash balances (SAR 34.5 M) and minimal leverage (debt‑to‑equity ~7%).
Valuation appears roughly fair, with the market price aligning closely to the DCF‑derived fair value (≈SAR 5.60) and a P/E of 28 versus an industry average of 26.2. Volatility is high at 36.8% over 30 days, yet beta is low (0.21), suggesting limited market‑wide sensitivity. The combination of robust dividend income, solid growth prospects, and a balanced risk profile makes the stock attractive for income‑focused investors, while the bearish technical backdrop advises caution on the near‑term.
Valuation appears roughly fair, with the market price aligning closely to the DCF‑derived fair value (≈SAR 5.60) and a P/E of 28 versus an industry average of 26.2. Volatility is high at 36.8% over 30 days, yet beta is low (0.21), suggesting limited market‑wide sensitivity. The combination of robust dividend income, solid growth prospects, and a balanced risk profile makes the stock attractive for income‑focused investors, while the bearish technical backdrop advises caution on the near‑term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages indicating bearish momentum
- High dividend yield providing income cushion
- Decreasing volume suggesting limited near‑term buying pressure
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth of 42.7% year‑over‑year
- Sustainable dividend payout with ample cash reserves
- Fair valuation relative to DCF and industry benchmarks
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term demand for healthcare services in Saudi Arabia
- Consistently high dividend yield supporting total return
- Low leverage and solid balance‑sheet strength
Key Metrics & Analysis
Financial Health
Revenue Growth42.70%
Profit Margin12.07%
P/E Ratio28.0
Debt/Equity6.92
P/B Ratio4.4
Op. Cash FlowSAR15.5M
Industry P/E26.2
Technical Analysis
TrendBearish
RSI40.1
SupportSAR 5.33
ResistanceSAR 6.65
MA 20SAR 5.83
MA 50SAR 6.10
MA 200SAR 7.17
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueSAR 5.60
GradeFair
TypeBlend
Dividend Yield16.07%
Risk Assessment
Beta0.21
Volatility36.78%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.